PCSK9 Antibody (YA1550)

製品番号: HY-P81805: データシート SDS COA User Guide for Antibodies
FAQs
Technical Support

PCSK9 Antibody (YA1550) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PCSK9.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

容量	価格（税別）	在庫状況	数量
無料サンプル		今すぐ申し込む
10 μL	$72	在庫あり	Estimated Time of Arrival: December 31
50 μL	$180	在庫あり	Estimated Time of Arrival: December 31
100 μL	$294	在庫あり	Estimated Time of Arrival: December 31
250 μL		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

おすすめ:

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Verification Image
Background
説明

製品説明

PCSK9 Antibody (YA1550) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PCSK9.

Host

Rabbit

Clonality

Recombinant, Monoclonal

分子量

Predicted band size: 74 kDa;

Observed band size: 65,80 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human

SwissProt ID

Q8NBP7

Gene ID

255738 [NCBI]

Immunogen

A synthetic peptide of human PCSK9 aa565-578.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-1:1000
IP IP: Immunoprecipitation	1:20

Sensitivity	Endogenous	純度	Affinity Purified
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG

Appearance

Liquid

Formulation

Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

輸送条件

Shipping with blue ice.

Verification Image

Western blot analysis of extracts from A431 (lane 2(20μg)), Mouse liver (lane 3(20μg)) and Rat liver (lane 4(20μg)) using PCSK9 Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (beta Actin, HY-P83730, 1/5000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Rabbit/Mouse IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

Background

Function：Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:17461796, PubMed:18197702, PubMed:18799458, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways

Subcellular Localization：Cytoplasm; Secreted; Endosome; Lysosome; Cell surface; Endoplasmic reticulum; Golgi apparatus

Expression：
Tissue_specificity:It is expressed in neuroepithelial tumors, colon cancers, hepatocytes, pancreatic cell lines, and Schwann cells.

Isoforms & Post-Translational Modification：Q8NBP7 has 2 isomers: Q8NBP7-1: 74286 Da (predicted); Q8NBP7-2: 20827 Da (predicted).
Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation;Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein;Phosphorylation protects the propeptide against proteolysis

Subunit：Monomer. Can self-associate to form dimers and higher multimers which may have increased LDLR degrading activity. The precursor protein but not the mature protein may form multimers. Interacts with APOB, VLDLR, LRP8/APOER2 and BACE1. The full-length immature form (pro-PCSK9) interacts with SCNN1A, SCNN1B and SCNN1G. The pro-PCSK9 form (via C-terminal domain) interacts with LDLR. Interacts (via the C-terminal domain) with ANXA2 (via repeat Annexin 1); the interaction inhibits the degradation of LDLR (PubMed:18799458)

RRID

AB_3103906

Database

Entrez Gene: 255738 Human

SwissProt: Q8NBP7 Human

OMIM: 603776 Human

Research Field

Signal Transduction

Synonyms

HCHOLA3; LDLCQ1; NARC1; Neural apoptosis regulated convertase 1; PC9; PCSK9; Proprotein convertase 9

ドキュメンテーション

Select Batch:

データシート (234 KB) SDS (251 KB)

COA (206 KB)

User Guide for Antibodies (1077 KB)